Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has received final Federal Drug Administration approval for Triamcinolone Acetonide Topical Aerosol, the generic version of Sun Pharma’s Kenalog® nasal spray. Our first to market shipments to our pharmacy customers have commenced.
Kenalog® Spray (Triamcinolone Acetonide Topical Aerosol, USP) is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Annual sales were approximately $16 million according to IMS Health.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Perrigo’s Chairman, President and CEO Joseph C. Papa stated, “This launch is another example of Perrigo’s investment and commitment to making quality healthcare more affordable for all consumers across the globe.”
